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Background: A number of small studies suggest that ultraﬁltration (UF) can improve outcomes in patients with
acute decompensated heart failure (ADHF), but substantial uncertainty remains. We conducted a systematic
review and meta-analysis with the primary goal of assessing the impact of UF on all-cause mortality in adults
with ADHF; the secondary outcomes included re-hospitalization, emergency outpatient visits, and potentially
deleterious effects (worsening renal function).
Methods:We searched theMedline (1966–2013), the Embase (1966–2013), the Cochrane Registry, the U.S. Clinical
Trials databases (2000–2013) and the abstracts from key scientiﬁcmeetings to identify studies comparing UFwith
usual care (diuretic therapy) in adults hospitalized with ADHF. We identiﬁed six randomized controlled trials
enrolling 523 patients. Studies were not heterogeneous and a ﬁxed effect model was used for all analysis.
Results: Unadjusted mortality was 13.3% among all diuretic patients as compared to 13.4% among UF recipients
(p = 0.81). When compared to treatment with diuretics alone, UF did not reduce all-cause mortality (HR: 0.99,
95% CI: 0.60 to 1.61; p = 0.65), re-hospitalizations for HF (HR: 0.96, 95% CI: 0.39 to 2.35; p = 0.92), or unscheduled
visits for heart failure (HR: 0.94, 95% CI: 0.36 to 2.50; p = 0.84). Furthermore, UFwas not associatedwith increased
risk of worsening renal function when compared to diuretic therapy (HR: 1.41, 95% CI: 0.89 to 2.22; p = 0.89).
Conclusions:UFdoesnot appear to reducemortality, re-hospitalization or unscheduledHFvisits in adultswithADHF.
At the present time data are insufﬁcient to support routine use of UF for acute HF.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.Introduction
Approximately one million Americans are hospitalized annually for
heart failure (HF) at a cost of approximately $40 billion [1]. Despite
advances in pharmacotherapy and medical devices, HF remains a
progressive condition characterized by frequent exacerbations and
hospital admissions. For patients with acute decompensated heart fail-
ure (ADHF), diuretics have been the mainstay of treatment for decades.
However, even with optimal diuretic use, approximately 5% of patients
with ADHF die during their acute hospitalization [1]. Ultraﬁltration
(UF) is a type of membrane ﬁltration where hydrostatic pressure forces
plasma water across a semipermeable membrane allowing movement
of water and small solutes (less than 20 KDa) based on the transliability and freedom from bias
Medicine, University of Iowa
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land Ltd. Open access under CC BY-Nmembrane pressure gradient between the blood and the ﬁltrate sides
of the ﬁlter [2]. UF has been available since the 1970s but has recently
received renewed attention because of promising results in a number
of small studies [3,4]as well as increased interest in ﬁnding more effec-
tive therapies for ADHF. The uncertainty over UF is reﬂected in a number
of clinical guidelines. Previous studies evaluating UF for treatment of
ADHF have mostly focused on intermediate endpoints (e.g., degree of
volume removal, weight loss) and have shown mixed results [3,5].
Moreover, a beneﬁt of UF on hard clinical endpoints (e.g., mortality,
re-hospitalization) has not been consistently demonstrated. Current
American college of cardiology (ACC)/American Heart association
(AHA) guidelines categorize UF as a class IIa recommendation recogniz-
ing that it is reasonable to apply this therapy in refractory congestion but
that additional studies are needed to deﬁne situations where patients
are most likely to beneﬁt.
In an effort to better elucidate the risks and beneﬁts associated with
UF, we performed a systematic literature review and meta-analysis of
the published and unpublished literature. Speciﬁcally, we set out to
examine the effectiveness of UF as compared to “usual care” for patients
hospitalizedwith ADHF.We evaluated the impact of UF onmortality, re-
hospitalization andunscheduledHFvisits.We also sought to examine its
impact on renal function, a potential adverse effect encountered in
clinical practice.C-ND license.
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Our analysis is based on the guidelines of theMeta-analysis of Obser-
vational Studies in Epidemiology Group [6].
Search strategy
With the assistance of a trained research librarian, we searched the
Medline (1946–2013), the Embase (1966–2013), the CINAHL (1981–
2013), the Web of Science (1899–2013), the Scopus (1960–2013), the
Cochrane Database of systematic Reviews (2005–2013), the Cochrane
Central Register of Controlled Trials (1898–2013), and the U.S. Clinical
Trials databases (2000–2013) to identify randomized controlled trials
and observational studies that compared UF to “usual care” (diuretic
therapy) in patients with ADHF. In addition, we reviewed meeting
abstracts for the 2000–2012 American College of Cardiology, the
American Heart Association, the European Society of Cardiology, the
Heart Failure Society of America and the European Society of Heart Fail-
ure. We also reviewed the reference lists of key articles to identify addi-
tional studies of potential relevance to our review. Search terms
included theMeSH headings for “diuretics”, or “epithelial sodium chan-
nel blocker”, or “epithelial sodium ion channel blocker”, or “sodium po-
tassium chloride symporter”, “heart decompensation”, “myocardial
failure”, “mortality”, “usual care”, “standard of care”, “renal failure”,
“re-hospitalization”, “ultraﬁltration”, or “CVVH”, “cohort as topic”, or
“observational study”, “randomized controlled trials as topic”, or
“random allocation”, or “clinical trial”. A full description of our search
strategy is included as Appendix1.
Study selection
We applied the following inclusion criteria in our review of poten-
tially eligible studies: 1. prospective randomized controlled trials
(RCTs) and/or observational studies; 2. adult patients aged N 18 years;
3. patients admitted with ADHF presenting with at least two signs of
volume overload (lower extremity edema, pleural effusion or pulmo-
nary edema on chest imaging, jugular venous pulsation N 10 cm
water) and 4. report of one-or-more study outcomes for both the UF
and control groups (all-cause mortality, re-hospitalization for any
cause, unscheduled medical visits for HF (whether ofﬁce or emergency
department visits) and change in renal function at discharge). Control
groups typically received usual care, though the precise deﬁnition of
usual care differed across studies as described below.
We excluded studies if: 1. wewere unable to obtain both the numer-
ator (i.e., number of patients experiencing a given outcome) and
denominator (i.e., number of patients at risk) for the UF and control
groups; 2. data appeared to duplicate another study; and 3. diuretics
were not withheld on admission in the UF group. In the UF group,
diuretics were withheld during the ﬁltration session and were resumed
afterwards with optimal dosing left to the discretion of the physicians;
thus, any potential beneﬁt would solely be attributed to UF.
Methodological quality
We evaluated trials for concealment of treatment allocation, clear
description of the design and completeness of follow up. The JADAD
scale was used to score study quality (range of 0–5, higher scores indi-
cating higher quality) [7].
Data abstraction
Weused a structured abstraction instrument (Appendix 2) to collect
study-level data including: 1. publication details (ﬁrst author's last
name, publication year); 2. study design (RCT or cohort); 3. patient
characteristics (age, sex, race and co-morbidities including hyperten-
sion, diabetes, coronary artery disease); 4. type of device used (UFgroup only); 5. rate and duration of ﬁltration (UF group only); and 6.
dose and method of diuretic administration-bolus versus continuous
(usual care group only).
Data extraction and information on study design, clinical and safety
outcomes were performed independently by 2 reviewers (N.M. and
S.M.). Discrepancies were resolved by consensus.
Outcome measure
The primary endpoint was all-cause mortality. The secondary end-
points included: 1. re-hospitalization for any cause; 2. unscheduled
visits for HF (whether ofﬁce or emergency department visits) and 3.
worsening of renal function at hospital discharge. Worsening of renal
function at discharge (varied from 24 to 96 h since admission) was de-
ﬁned as either an elevation in serumcreatinine (greater than 0.3 mg/dl)
or new requirement for dialysis [8].
Statistical analysis
We used graphical and tabular methods to summarize the results of
our literature search and systematic review. We presented key informa-
tion about eligible studies (e.g., authorship, study year, setting) using sum-
mary Tables. We calculated summary hazard ratios and 95% conﬁdence
intervals for all clinical outcomes (e.g., mortality, re-hospitalization) by
pooling published raw data available for each study using standard
meta-analytic methods. We attempted to obtain individual patient-level
data from the authors of published studies to allow for more detailed
pooling, but our efforts were unsuccessful. Hazard Ratios (HRs) were
transformed logarithmically since they do not follow a normal distribu-
tion. The standard error was calculated from Log HR and the correspond-
ing 95% conﬁdence interval. We used the inverse variance method to
achieve a weighted estimate of the combined overall effect [6].
We assessed the results for heterogeneity in our analysis by examin-
ing the forest plots and then calculating a Q statistic, which we
compared with the I2 index. The Q statistic indicates the statistical sig-
niﬁcance of the homogeneity hypothesis and the I2 index measures
the extent of the heterogeneity [9]. We considered the presence of sig-
niﬁcant heterogeneity at the 5% level of signiﬁcance (for the Q test) and
values of I2 exceeding 56% as an indicator of signiﬁcant heterogeneity
according to established methods [10]. Combined estimate was obtain-
ed using the ﬁxed-effects model (Mantel–Haenszel method) [6]. Publi-
cation bias was assessed by visual examination of the funnel plots and
by using Egger's asymmetry test [11].
We conducted a number of sensitivity analyses to evaluate the
robustness of our ﬁndings. In particular, we evaluated UF in: 1. studies
that used newer less invasive techniques as shown in Table 1; 2. all
studies except those utilizing high ﬁltration rates of 500 ml/h [4,12] as
they are less commonly utilized in clinical practice; 3. all studies except
those using a single 8 hour ﬁltration session [12] as it increases the risk
of hypotension and 4. studies with more than 30 day follow up.
All probability values were 2 tailed and p = .05 was considered sta-
tistically signiﬁcant. All analyses were performed using Microsoft excel
version 2010. Our meta-analysis was considered to be exempt from
institutional review board (IRB) review as per University of Iowa IRB
guidelines since we did not obtain or had access to individually identiﬁ-
able human participant information.
Results
Studies and patient characteristics
The literature search yielded 473 potential studies. After application
of all inclusion/exclusion criteria we identiﬁed six RCTs and no cohort
studies for inclusion in our ﬁnal analysis (Fig. 1). Study quality was gen-
erally low-to-intermediate (four studies with JADAD scale of 2 and two
with scale of 3) [4,13]. Table 1 shows characteristics of the included
Table 1
Characteristics of included studies.
Study Year Total N Patients on
UF N (%)
Patients on
diuretics
(continuous/
bolus)
Mean
age
(range in
years)
Men
(%)
Caucasian
(%)
DM
(%)
HTN
(%)
CAD
(%)
NYHA
class
%
with
EF
b40%
Mean
F/U
(days)
UF
duration
(hours)
UF device JADAD
scale
Baseline
serum
creatinine
(mg/dL)
Badawy 2012 40 20 (50.0%) 20 (20/0) 63
(51–75)
65.1 NR 58.2 68.1 63.0 III
(68%)
IV
(32%)
73.2 30 72 Traditional
more
invasive
2 1.40
Bart 2005 40 20 (50.0%) 20 (0/20) 68
(55–73)
72.2 NR 44.1 62.0 42.1 III
(26%)
IV
(74%)
73.1 30 8 Less
invasive
Aquadex
2 1.65
Bart 2012 188 94 (50.0%) 94 (0/94) 68
(58–78)
75.2 74.2 66.3 85.2 61.1 NR NR 60 96 Less
invasive
Aquadex
3 2.00
Costanzo 2007 200 100 (50.0%) 100 (32/68) 62
(48–76)
69.3 53.2 50.4 74.3 52.2 III
(55%)
IV
(45%)
70.2 90 48 Less
invasive
Aquadex
3 1.50
Hanna 2012 36 19 (52.7%) 17 (0/17) 60
(48–72)
80.4 85.3 34.1 47.4 40.2 III
(63%)
IV
(37%)
100.0 90 48 Traditional
more
invasive
2 1.65
Rogers 2008 19 9 (47.4%) 10 (0/10) 59
(43–75)
69.1 42.1 64.2 59.1 69.1 III
(48%)
IV
(52%)
100.0 2 48 Less
invasive
Aquadex
2 1.65
Overall 523 262
(50.1%)
261(52/209) 64 74.2 72.3 52.3 62.2 53.3
Baseline characteristics of included studies. There were a total of 523 patients: 262 received UF and 261 received usual care (diuretic therapy). Among the patients who received diuretic
therapy, 20% received IV diuretic as a continuous infusion while 80% received it as a bolus therapy. Mean follow-up was 50 days and median follow-up was 45 days. It is important to
mention in Bart's study [13] patients had a baseline serum creatinine of 2 mg/dl compared to the baseline serum creatinine of 1.5 to 1.6 in the remaining studies. Three out of the six trials
were funded by industry.
Abbreviations: (UF = ultraﬁltration; N = number; DM = diabetes mellitus; HTN = hypertension; CAD = coronary artery disease; NYHA = New York Heart Association;
EF = ejection fraction; F/U = follow up; NR = not reported; RCT = randomized clinical trial; N/A = not applicable).
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261 to usual care). Themean agewas 64, 74% of subjects weremen, and
mean follow up duration was 50 days. All participants were New York
Heart Association (NYHA) class III and IV.
Diuretics were administered as continuous infusion in three trials
[4,8,14] and as boluses in the remaining studies. In the study conducted
by Costanzo and colleagues, both methods were used and compared toFig. 1. Flow diagram representing the study selection process for our analysis. It is worthwhilem
for UF as they were of small size (less than 30 patients). Furthermore, the primary endpoint in t
for mortality, re-hospitalization and worsening renal function.UF [4]. Furosemidewas the diuretic of choice across included trials. Four
of the included trials [4,12,13,15] used the federal drug association ap-
proved ultraﬁltration system (AQUADEX) [16]. This system is based
on less invasive peripheral venous access with ﬁltration rates that can
go as high as 500 ml/h; thus, it could be done outside of an intensive
care unit setting. On the other hand, the remaining trials adopted a con-
tinuous 24–96 hour session at an average rate of 200 ml/h whichentioning that the four excluded randomized trials did not show a strong beneﬁt or harm
hose excluded trials was effect of UF on hemodynamic variables with few events recorded
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these treatment sessionswould need to bedone in an intensive care set-
ting (Table 1).
Outcomes
Raw outcomes for each of the six studies are included in Table 2.
Effect of UF on all-cause mortality
In our pooled analysis, we found that UF was not associated with
a signiﬁcant change in all-cause mortality (HR: 0.99, 95% CI: 0.60
to 1.61; p = 0.65) (Fig. 2). There was no signiﬁcant heterogeneity
(Q test with p = 0.65 and I2 = 0).
Effect of UF on re-hospitalization for any cause
In analysis of studies focusing on all-cause re-hospitalization, UF did
not result in a substantial reduction in re-hospitalization (HR: 0.96, 95%
CI: 0.39 to 2.35; p = 0.75) (Fig. 2). Therewasmore notable heterogene-
ity in analysis of re-hospitalization but it did not reach statistical signif-
icance (Q test with p = 0.15 and I2 = 54%).
Effect of UF on unscheduled visits (whether emergency department or ofﬁce
visits) for heart failure
In our analysis focusing on unscheduled outpatient visits, UF did not
reduce the need for unscheduled visits for heart failure (HR: 0.94, 95%
CI: 0.36 to 2.50; p = 0.84) (Fig. 3). There was signiﬁcant heterogeneity
in our analysis of unscheduled medical visits (Q test with p b 0.05 and
I2 = 65%).
Effect of UF on renal function
We found no evidence that UF worsened renal function during the
initial inpatient admission when compared to usual care (HR: 1.41,
95% CI: 0.89 to 2.22; p = 0.89) (Fig. 3); long-term follow-up data was
available for only two studies, precluding us from conducting pooled
analysis. There was no signiﬁcant heterogeneity (Q test with p = 0.58
and I2 = 0).
Publication bias
Based on the Egger's test (p = 0.1) and based on visual inspection of
the funnel plot for all-cause mortality (Fig. 4), there is no evidence of
publication bias in out meta-analysis [11].Table 2
Raw outcomes for each individual study.
Study Year All-cause mortalita Re-hospitalization
any causea
UF Usual UF
Badawy 2012 3/20
(15.0%)
5/20
(25.0%)
NR
Bart 2005 1/20
(5.0%)
0/20
(0.0%)
NR
Bart 2012 16/90
(17.8%)
13/93
(14.0%)
46/90
(51.1%)
Costanzo 2007 9/98
(9.2%)
11/98
(11.1%)
16/98
(16.3%)
Hanna 2012 4/19
(21.1%)
4/17
(24.0%)
8/19
(42.1%)
Rogers 2008 NR NR
Overall 33/247
(13.4%)
33/248
(13.3%)
70/207
(33.8%)
Five out of six studies evaluated the impact of ultraﬁltration on all-cause mortality and worse
hospitalization for any cause and on unscheduled medical visits.
Abbreviations: (UF=ultraﬁltration; NR=not reported).
a All-causemortality, re-hospitalization and unscheduled follow-up visits for HRwere reporte
studies.Sensitivity analysis
Results for pre-speciﬁed subgroups are shown inAppendix 3 (e Figs. 1,
2, 3, and 4). For all-cause mortality, re-hospitalization, and worsening
renal function, UFwas not associatedwith change in outcomewhen com-
pared to usual care across all subgroups (e Figs. 1, 2 and 4). However, for
unscheduledmedical visits (e Fig. 3), UF was not associated with any sig-
niﬁcant changes across all subgroups except the one involving studies
with lower ﬁltration rates where it was associated with increased risk
for unscheduled visits (HR: 1.58, 95% CI: 1.18 to 2.12; p b 0.05).
Discussion
Our systematic review and meta-analysis of UF for ADHF revealed a
number of importantﬁndings. First, we found thatUF did not reduce all-
cause mortality, re-hospitalization or unscheduled medical visits
(emergency department or clinic) for heart failure. Second, we found
no evidence that UF worsened renal function. Third, we found surpris-
ingly few studies evaluating the effectiveness of a therapy that is prom-
ising and used with some regularity for hospitalized heart failure
patients. Each of these ﬁndings merits further discussion.
First, our analysis showed that UF had no effect on all-cause mortal-
ity, re-hospitalization or unscheduled medical visits. Our ﬁndings were
consistent in subgroup analyses stratiﬁed by patient age, sex, and ejec-
tion fraction to the degree that the data allowed. Ourﬁnding that UF had
no impact is sobering and should give pause. If UF does not impact any
of these key study endpoints for hospitalized patients with ADHF one
might call into questionwhether UFmeets the threshold for an effective
therapy. At a minimum, we would suggest that current clinical practice
guidelines that recommend UF as a Class IIa treatment carefully consid-
er whether the current rating should be updated pending stronger data
on clinical effectiveness.
Second, we found no evidence that UFworsened renal function. This
is consistent with previous published reports, which showed that UF
was more effective at removing ﬂuid, and improving dyspnea scores
without a signiﬁcant change in serum creatinine [3,17]. It is worthwhile
mentioning that we noted a trend of worsening renal function favoring
diuretics (Fig. 3) even though it did not reach statistical signiﬁcance.
However, it is difﬁcult to derive any conclusions as the deﬁnition of
worsening renal function varied across groups (was deﬁned as eleva-
tion in serum creatine at 24–48 h since admission in some studies ver-
sus 96 h in other studies). Moreover, there is potential for confounding
related to endpoint variation between the trials; speciﬁcally, worseningfor Unscheduled medical visitsa Worsening renal function
Usual UF Usual UF Usual
NR 1/20
(5.0%)
1/20
(5.0%)
NR NR
37/93
(39.8%)
19/90
(21.1%)
13/93
(13.9%)
17/90
(18.9%)
14/93
(15.1%)
28/98
(28.6%)
14/98
(14.3%)
29/98
(29.6%)
18/98
(18.4%)
15/98
(15.3%)
6/17
(35.3%)
4/19
(21.1%)
1/17
(5.6%)
6/19
(32.0%)
4/17
(24.0%)
NR 6/9
(67.7%)
5/10
(50.0%)
60/208
(28.9%)
37/207
(17.9%)
43/208
(20.7%)
48/236
(20.3%)
39/238
(16.4%)
ning renal function. Only three out of six trials evaluated impact of ultraﬁltration on re-
d across the entire follow-upperiod,which ranged from30days to 90 days across different
Fig. 2. Forest plot representing effect of UF on all-cause mortality and re-hospitalization. As shown in the ﬁgure, ultraﬁltration was not associated with reduction in all-cause
mortality (HR = 0.99, 95% CI [0.60–1.61], p = 0.65). Similarly, there seems to be no association between re-hospitalization and ultraﬁltration (HR = 0.96, 95% CI [0.39–
2.35], p = 0.75). (CI = Conﬁdence Interval).
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was a secondary endpoint in the remaining studies.
Third, after an extensive literature review we identiﬁed only six
studies that rigorously evaluated UF. All of the studies were RCTs
which represent an important strength for our analysis and any poten-
tial conclusions that wemay derive. It is also important to acknowledge
that the included studies were comprised largely of men (74.2%) and
whites (72.3%) calling into question how best to extrapolate our ﬁnd-
ings to the diverse U.S. heart failure population. Moreover, there was
no notable crossover in the trials and we obtained similar results
when did our analysis according to treatment received rather than in-
tention to treat. We are unaware of any prior published meta-analyses
evaluatingUF for ADHF. However, it is important to note that our resultsFig. 3. Forest plot representing effect of UF on unscheduled medical visits (ofﬁce and emergenc
after admission). As shown in the ﬁgure, UF is not associatedwith reduction in unscheduled visi
when compared to diuretic (HR = 1.41, 95% CI [0.89–2.22], p = 0.89). (CI = Conﬁdence Intemirror the ﬁndings of preliminary results presented in abstract form
[18].
We were unable to obtain patient-level data, precluding us from
performing multilevel meta-regression. Nevertheless, we did perform
multiple subgroup analyses and were unable to identify any particular
UF regimen or patient populations that appeared to derive signiﬁcant
beneﬁt. Going forward, further studies are needed to better deﬁne
which- if any- ADHF patient populations might beneﬁt from UF. For in-
stance, we suggest that UF may be more appropriate for patients with
baseline kidney disease who are refractory to diuretic therapy rather
than providing it to all patients with ADHF.
Finally, a complete understanding of our results must take into
account the cost associated with UF. Bradley et al. estimated that UFy department visits) and on worsening renal function at discharge (measured at 24–96 h
ts (HR = 0.94, 95% CI [0.36–2.50], p = 0.84) or increased risk of worsening renal function
rval).
Fig. 4. Funnel plot for all-cause mortality of the included studies in our analysis. Based on
visual inspection, there is no evidence of publication bias.
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uretic therapy [19]. The additional cost has been attributed to the ﬁlters
used per machine, nursing cost per shift, cost of heparin infusions, and
physician fees [20,21]. Production of lower cost UF supplies and staff
training could improve the cost-effectiveness of UF when compared to
diuretic therapy. Thus, our results suggest that in the absence of more
compelling data detailing the beneﬁts of UF, the costs of treatment are
difﬁcult to justify from either a clinical or economic standpoint.
Limitations of the study
There are several limitations of our analysis. First, there was incon-
sistency in the UF protocol used across the different RCTs; speciﬁcally
the two most robust studies (Costanzo [4] and Bart [13]) investigated
very different patient populations and took different approaches in
study design. Costanzo's study [4] involved UF as a primary therapy
(i.e. the protocol did not require failure of initial diuretic therapy for
entry), while study by Bart [13] randomized patients with ADHF, wors-
ening renal function and persistent volume overload to a strategy of UF
versus stepped pharmacological management [22]. Given continued
uncertainty about the ideal dosing of UF [23], we were unable to deci-
sively determine whether results might have differed across various
UF protocols. Likewise, there was variability in the diuretic regimens
(speciﬁcally in the dose and method of administration) used in the
usual care arms across studies; future research should carefully consider
how diuretics are used. Second, the included studies were generally
small single-center studies of short term follow-up and low-
intermediate quality which presents challenges in generalizability of
the data. Third, three of the six included trials were funded by industry
which could potentially bias the results (Bart [12], Costanzo [4] and
Rogers [15] were funded by CHF Solutions, Inc.). Potential overlap may
additionally limit our analysis; speciﬁcally Rogers's trial [15] was a
sub-study of the trial conducted by Costanzo [4].
Conclusion
In summary, we found that UF did not reduce mortality, re-
hospitalizations or unscheduled follow-up visits in patients with
ADHF. Given the increased cost of UF when compared to diuretic
therapy, we believe that it is difﬁcult to justify the routine use of
UF in the absence of more robust data demonstrating clinical effec-
tiveness. UF represents a promising novel approach to volume man-
agement but more investigation is needed to deﬁne its role in
patients with ADHF.Funding sources
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